Cupid Secures Rs. 16.23 Crore Orders For Male Condoms From Central Medical Services Society

Cupid Limited, a leading manufacturer, has garnered orders totalling Rs. 16.23 crores from the Central Medical Services Society (CMSS) for the supply of male condoms, the company informed in a press statement on Monday. Established as a Central Procurement Agency (CPA) with Cabinet approval, CMSS plays a crucial role in streamlining drug procurement and distribution for the Department of Health & Family Welfare (DoHFW), under the Ministry of Health and Family Welfare, Government of India.

Cupid successfully secured two separate orders for male condoms from CMSS, amounting to Rs. 9.65 crores and Rs. 6.58 crores, respectively. The company aims to fulfil these orders by April 2024, as disclosed in the exchange filing on January 8, 2024.

Aditya Halwasiya, Managing Director of Cupid , expressed excitement about this significant allocation from the Government of India, highlighting the company’s unwavering commitment to supporting the government’s vision of promoting a safe and healthy lifestyle for all citizens. He stated, “This collaboration underscores the importance of ensuring access to vital resources for the well-being of the community at large.”

Furthermore, Halwasiya emphasised Cupid Limited’s alignment with the Government of India’s initiative to “Help India Play Safe.” He mentioned that Cupid Limited’s proposed production capacity expansion in the next 18-24 months positions the company well for future orders from the government.

This development not only strengthens Cupid Limited’s partnership with the Government of India but also reflects the company’s dedication to contributing to public health initiatives. The successful execution of these orders is anticipated to play a vital role in advancing the accessibility of essential resources within the healthcare sector.

Related Posts

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta, a UK-based clinical stage biotech, is differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform

Stem cell therapy for autism only in approved clinical trials: Centre

Stem cell therapy for autism only in approved clinical trials: Centre